January 18, 2018 11:17 AM ET


Company Overview of aTyr Pharma, Inc.

Company Overview

aTyr Pharma, Inc., a clinical stage biotherapeutics company, engages in the discovery and development of Physiocrine-based therapeutics for patients suffering from severe and rare diseases. The company develops Resolaris, which is in Phase Ib/II clinical trials for treating patients with facioscapulohumeral muscular dystrophy (FSHD), early onset FSHD, and limb-girdle muscular dystrophy, as well as under evaluation to treat Duchenne muscular dystrophy. Its discovery program includes Stalaris for treating interstitial lung disease with an immune component; and preclinical research program comprises Project ORCA to treat therapeutic applications of Physiocrines. The company was founded in 2005 ...

3545 John Hopkins Court

Suite 250

San Diego, CA 92121

United States

Founded in 2005

58 Employees





Key Executives for aTyr Pharma, Inc.

CEO, President & Director
Age: 45
Total Annual Compensation: $315.4K
Chief Business Officer
Age: 45
Total Annual Compensation: $398.8K
Compensation as of Fiscal Year 2016.

aTyr Pharma, Inc. Key Developments

aTyr Pharma, Inc. Presents at 36th Annual J.P. Morgan Healthcare Conference, Jan-11-2018 08:00 AM

aTyr Pharma, Inc. Presents at 36th Annual J.P. Morgan Healthcare Conference, Jan-11-2018 08:00 AM. Venue: Westin St. Francis Hotel, 335 Powell Street, San Francisco, California, United States. Speakers: Sanjay S. Shukla, CEO, President & Director.

aTyr Pharma, Inc. Presents at BIO One-on-One Partnering™, Jan-07-2018

aTyr Pharma, Inc. Presents at BIO One-on-One Partnering™, Jan-07-2018 . Venue: San Francisco, California, United States.

aTyr Pharma, Inc. Announces Amendment to the Loan and Security Agreement

On December 22, 2017, aTyr Pharma, Inc. entered into an amendment to the Loan and Security Agreement with Silicon Valley Bank and Solar Capital Ltd. The Loan Amendment amends that certain Loan and Security Agreement between the Company and the Lenders, dated as of November 18, 2016. The Loan Agreement provides for up to $20.0 million in term loans in three tranches. The Loan Amendment modifies the milestone requirements for the draw of the third tranche of the loan to include Australia as a qualifying geography for the initiation of a Phase 1 clinical trial for iMod.Fc. In connection with the Loan Amendment, the third tranche of $5.0 million was funded on December 22, 2017.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3Bar Biologics Inc. United States

Recent Private Companies Transactions

Private Placement
August 27, 2017

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
Tax Management Inc United States
NYC2012, Inc. United States
John F. Kennedy Center For The Performing Arts United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact aTyr Pharma, Inc., please visit www.atyrpharma.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.